IDH1 and astrocytoma (excluding glioblastoma): Large-scale sequencing studies revealed that heterozygous mutations in both cytosolic IDH1 and mitochondrial IDH2 are highly prevalent in World Health Organization (WHO) grade II and III astrocytomas or oligodendrogliomas and in secondary glioblastomas9,10.